Best bargain stocks to buy is a simple but tricky concept. Whenever shares trade lower than an established multiple, whether that by earnings, sales, book or some other metric, there might be a reason for it. In many cases, it’s not a good one.Let’s face reality here. In the age of the internet, it’s difficult for a well-known publicly traded enterprise to be woefully undervalued. That’s because information is readily available. If the market genuinely believed there was value to be extracted, the shares in ...

Eoneren BioNTech: Financial Health And Market Sentiment Amidst Transition Since my December update on the company's potential in oncology, BioNTech (NASDAQ:BNTX) is down another 17%. Due to COVID comparisons, revenue and profit had been on the decline at that time, but I reiterated BioNTech's long-term growth potential. This Wednesday, its stock is trading lower after reporting Q4 earnings, even touching 52-week lows in intraday trading. The article below takes a look at any important changes. Based on a ...

BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Conference Call March 20, 2024 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy and IR Ugur Sahin - Co-Founder and CEO Ozlem Tureci - Chief Medical Officer and Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Bill Maughan - Canaccord Ivy Wang - Jefferies Yaron Werber - TD Cowen Etzer Darout - BMO Capital Jessica Fye - JPMorgan Simon Baker - Redburn Sara Vernizzi - ...

FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered or to be registered, pursuant to Section 12(b) of the Act | | Trading | | | --- | --- | --- | | Title of each class | Symbol(s) | Name of each excha ...

Financial Performance - Total revenues for Q4 2023 were €1,479.0 million, a decrease of 65.4% compared to €4,278.3 million in Q4 2022. For the full year 2023, total revenues were €3,819.0 million, down 78.0% from €17,310.6 million in 2022[20]. - Net profit for Q4 2023 was €457.9 million, a decline of 80.0% from €2,278.7 million in Q4 2022. For the full year 2023, net profit was €930.3 million, down 90.2% from €9,434.4 million in 2022[7]. - Diluted earnings per share for Q4 2023 were €1.90, compared to €9.26 in Q4 2022, representing a decrease of 79.5%. For the full year 2023, diluted earnings per share were €3.83, down 89.9% from €37.77 in 2022[8]. - Operating profit for the three months ended December 31, 2023, was €457.9 million, compared to €205.3 million for the same period in 2022, representing a 122% increase[96]. - Profit before tax for the three months ended December 31, 2023, was €663.2 million, down from €3,172.6 million in the same period of 2022, indicating a significant decline[96]. Research and Development - Research and development (R&D) expenses for Q4 2023 were €577.8 million, an increase of 13.3% from €509.8 million in Q4 2022. For the full year 2023, R&D expenses were €1,783.1 million, up 15.9% from €1,537.0 million in 2022[22]. - BioNTech aims to achieve product approvals in ten oncological indications by 2030, with plans for ten or more potentially registrational oncology trials running by the end of 2024[19]. - The company has 10 ongoing Phase 2 and 3 trials in its oncology pipeline, with plans for its first oncology launch in 2026 and aims for ten indication approvals by 2030[56]. - A pivotal Phase 2 clinical trial in relapsed/refractory germ cell tumors is planned to start in 2024[41]. - BioNTech initiated three first-in-human Phase 1 clinical trials for vaccine candidates addressing shingles, tuberculosis, and mpox in 2023[68]. Cash and Investments - Cash and cash equivalents, along with security investments, reached €17.7 billion as of December 31, 2023, comprising €11.7 billion in cash and €6.0 billion in security investments[24]. - Cash and cash equivalents as of December 31, 2023, were €11,663.7 million, down from €13,875.1 million at the end of the previous year[97]. - The company reported finance income of €162.2 million in Q4 2023, a significant increase from €38.8 million in Q4 2022[78]. - Net cash flows from operating activities for the three months ended December 31, 2023, were €850.9 million, slightly up from €829.2 million in the previous year[96]. - Net cash flows used in investing activities for the three months ended December 31, 2023, were €(2,695.1) million, compared to €(161.0) million in the same period of 2022[97]. Strategic Partnerships and Collaborations - The company delivered over 400 million COVID-19 vaccine doses worldwide in 2023, including the XBB.1.5 variant-adapted monovalent COVID-19 vaccine[15]. - BioNTech's collaboration with Pfizer is crucial for revenue generation, with potential impacts from inventory write-downs by Pfizer affecting BioNTech's revenues[52]. - BioNTech aims to reach up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030 through a partnership with the UK government[69]. - The company has established a multi-year partnership with the State of Victoria, Australia, to set up a clinical-scale mRNA manufacturing facility and an mRNA Innovation Center in Melbourne[69]. Corporate Governance and ESG - BioNTech's ESG rating from ISS is "Prime" with an overall corporate rating of B-, placing it among the top 10% of rated companies in the pharmaceutical sector[46]. - BioNTech's near-term science-based emissions reduction targets have been approved by the Science Based Targets initiative, aligning with the UN's Paris Climate Agreement[72]. Future Outlook - The 2024 revenue guidance is set between €2.5 billion and €3.1 billion, with R&D expenses projected at €2.4 billion to €2.6 billion[11]. - BioNTech expects group revenue for the full 2024 financial year to be in the range of €2.5 - €3.1 billion, reflecting various assumptions including COVID-19 vaccine uptake and regulatory approvals[52]. - The company plans to invest in a research and development hub in Cambridge, UK, which is expected to employ over 70 additional scientists[69]. Acquisitions and Enhancements - The acquisition of InstaDeep Ltd added approximately 290 skilled professionals to BioNTech, enhancing its capabilities in AI and ML technologies[69]. - The company completed construction of its first proprietary plasmid DNA manufacturing facility in Marburg, Germany, enhancing its production capabilities[44].

Follow Invezz on Telegram , Twitter , and Google News for instant updates >BioNTech SE (NASDAQ: BNTX) is down nearly 5.0% in premarket on Wednesday after reporting disappointing financial results for the fourth quarter.BioNTech stock down on muted guidanceCopy link to sectionThe stock is being hit because $BNTX did not issue an impressive guidance either. It now expects revenue to fall between €2.5 billion and €3.1 billion ($2.71 billion to $3.36 billion) this year. Analysts, in comparison, were at €3.44 bi ...

  Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024Aiming for first oncology launch in 2026 and ten indication approvals by 2030 as part of BioNTech's strategy to develop combinatorial and synergistic therapeutic approachesEntered strategic collaborations with Biotheus, DualityBio, Medilink and OncoC4 to complement clinical oncology pipeline with innovative antibody-drug conjugate (ADC) and immuno-modulator ...

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. She will join BioNTech from Novartis AG ("Novartis") and succeed Sean Marett in this role. Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompa ...

MAINZ, Germany, March 11, 2024 – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research ("AACR") Annual Meeting 2024 in San Diego, California, from April 5-10, 2024. The oral and poster presentations will feature BioNTech's investigational mRNA-based cancer vaccine and novel investigational antibody-drug conjugate ("ADC") approaches. "This year's AACR presentations feature ca ...

MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024. The oral and poster presentations will feature BioNTech’s investigational mRNA-based cancer vaccine and novel investigational antibody-drug conjugate (“ADC”) approaches. “This year’s AACR presentations feature can ...